Brain-targeted intranasal delivery of protein-based gene therapy for treatment of ischemic stroke

Gene therapy using a protein-based CRISPR system in the brain has practical limitations due to current delivery systems, especially in the presence of arterial occlusion. To overcome these obstacles and improve stability, we designed a system for intranasal administration of gene therapy for the treatment of ischemic stroke. Nanoparticles containing the protein-based CRISPR/dCas9 system targeting were delivered intranasally to the brain in a mouse model of ischemic stroke. The CRISPR/dCas9 system was encapsulated with calcium phosphate (CaP) nanoparticles to prevent them from being degraded. They were then conjugated with β-hydroxybutyrates (bHb) to target monocarboxylic acid transporter 1 (MCT1) in nasal epithelial cells to facilitate their transfer into the brain. Human nasal epithelial cells were shown to uptake and transfer nanoparticles to human brain endothelial cells with high efficiency . The intranasal administration of the dCas9/CaP/PEI-PEG-bHb nanoparticles in mice effectively upregulated the target gene, , in the brain, decreased cerebral edema and increased survival after permanent middle cerebral artery occlusion. Additionally, we observed no significant toxicity associated with intranasal administration of the nanoparticles, highlighting the safety of this approach. This study demonstrates that the proposed protein-based CRISPR-dCas9 system targeting neuroprotective genes in general, and in particular, can be a potential novel therapy for acute ischemic stroke.